{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T19:46:25Z","timestamp":1740167185461,"version":"3.37.3"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T00:00:00Z","timestamp":1725580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T00:00:00Z","timestamp":1725580800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s40120-024-00657-y","type":"journal-article","created":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T15:03:14Z","timestamp":1725634994000},"page":"1527-1533","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Symptoms of Hereditary Transthyretin Amyloidosis: The Patient and Physician Perspective"],"prefix":"10.1007","volume":"13","author":[{"given":"Michael","family":"Lane","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7584-7447","authenticated-orcid":false,"given":"Michael","family":"Polydefkis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,9,6]]},"reference":[{"key":"657_CR1","doi-asserted-by":"publisher","first-page":"109","DOI":"10.2147\/TCRM.S219979","volume":"16","author":"M Luigetti","year":"2020","unstructured":"Luigetti M, Romano A, Di Paolantonio A, Bisogni G, Sabatelli M. Diagnosis and treatment of hereditary transthyretin amyloidosis (hATTR) polyneuropathy: current perspectives on improving patient care. Ther Clin Risk Manag. 2020;16:109\u201323.","journal-title":"Ther Clin Risk Manag"},{"key":"657_CR2","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.3390\/biomedicines10092073","volume":"10","author":"C Cambieri","year":"2022","unstructured":"Cambieri C, Libonati L, Moret F, et al. The silent period for small fiber sensory neuropathy assessment in a mixed cohort of transthyretin-mediated amyloidosis. Biomedicines. 2022;10:2073.","journal-title":"Biomedicines"},{"issue":"6","key":"657_CR3","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1136\/jnnp-2021-327909","volume":"93","author":"A Carroll","year":"2022","unstructured":"Carroll A, Dyck PJ, de Carvalho M, et al. Novel approaches to diagnosis and management of hereditary transthyretin amyloidosis. J Neurol Neurosurg Psychiatry. 2022;93(6):668\u201378.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3","key":"657_CR4","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1007\/s10741-021-10080-2","volume":"27","author":"J Nativi-Nicolau","year":"2022","unstructured":"Nativi-Nicolau J, Karam C, Khella S, Maurer M. Screening for ATTR amyloidosis in the clinic: overlapping disorders, misdiagnosis, and multiorgan awareness. Heart Fail Rev. 2022;27(3):785\u201393.","journal-title":"Heart Fail Rev"},{"key":"657_CR5","doi-asserted-by":"publisher","first-page":"749","DOI":"10.2147\/TCRM.S185677","volume":"16","author":"M Benson","year":"2020","unstructured":"Benson M, Dasgupta N, Rao R. Diagnosis and screening of patients with hereditary transthyretin amyloidosis (hATTR): current strategies and guidelines. Ther Clin Risk Manag. 2020;16:749\u201358.","journal-title":"Ther Clin Risk Manag"},{"key":"657_CR6","doi-asserted-by":"publisher","first-page":"S65","DOI":"10.1007\/s10286-019-00627-7","volume":"29","author":"I Bentellis","year":"2019","unstructured":"Bentellis I, Amarenco G, Gam\u00e9 X, et al. Diagnosis and treatment of urinary and sexual dysfunction in hereditary TTR amyloidosis. Clin Auton Res. 2019;29:S65\u201374.","journal-title":"Clin Auton Res"},{"key":"657_CR7","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s41687-020-00273-y","volume":"5","author":"A Lovley","year":"2021","unstructured":"Lovley A, Raymond K, Guthrie S, Pollock M, Sanchorawala V, White MK. Patient-reported burden of hereditary transthyretin amyloidosis on functioning and well-being. J Patient Rep Outcomes. 2021;5:3.","journal-title":"J Patient Rep Outcomes"},{"issue":"3","key":"657_CR8","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1080\/13506129.2022.2043270","volume":"29","author":"FA Barroso","year":"2022","unstructured":"Barroso FA, Coelho T, Dispenzieri A, et al. Characteristics of patients with autonomic dysfunction in the transthyretin amyloidosis outcomes survey (THAOS). Amyloid. 2022;29(3):175\u201383.","journal-title":"Amyloid"},{"key":"657_CR9","doi-asserted-by":"publisher","first-page":"B99","DOI":"10.1093\/eurheartjsupp\/suad082","volume":"25","author":"M Mallus","year":"2023","unstructured":"Mallus M, Rizzello V. Treatment of amyloidosis: present and future. Eur Heart J Suppl. 2023;25:B99\u2013103.","journal-title":"Eur Heart J Suppl"},{"key":"657_CR10","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s00392-020-01799-3","volume":"110","author":"A Yilmaz","year":"2021","unstructured":"Yilmaz A, Bauersachs J, Bengel F, et al. Diagnosis and treatment of cardiac amyloidosis: position statement of the German Cardiac Society (DGK). Clin Res Cardiol. 2021;110:479\u2013506.","journal-title":"Clin Res Cardiol"},{"key":"657_CR11","unstructured":"Sekijima Y, Nakamura K. Hereditary transthyretin amyloidosis. 2001 Nov 5 [Updated 2024 May 30]. In: GeneReviews\u00ae [Internet]. Seattle (WA): University of Washington, Seattle."},{"key":"657_CR12","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1007\/s13311-021-01154-y","volume":"18","author":"L Obici","year":"2021","unstructured":"Obici L, Mussinelli R. Current and emerging therapies for hereditary transthyretin amyloidosis: strides towards a brighter future. Neurotherapeutics. 2021;18:2286\u2013302.","journal-title":"Neurotherapeutics"},{"key":"657_CR13","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1080\/13506129.2022.2035354","volume":"29","author":"T Damy","year":"2022","unstructured":"Damy T, Adam C, Bridoux F, et al. Amyloidosis from the patient perspective: the French daily impact of amyloidosis study. Amyloid. 2022;29:165\u201374.","journal-title":"Amyloid"},{"key":"657_CR14","doi-asserted-by":"publisher","first-page":"2418","DOI":"10.1002\/ehf2.12793","volume":"7","author":"D Dang","year":"2020","unstructured":"Dang D, Fournier P, Cariou E, et al. Gateway and journey of patients with cardiac amyloidosis. ESC Heart Fail. 2020;7:2418\u201330.","journal-title":"ESC Heart Fail"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-024-00657-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-024-00657-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-024-00657-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T12:26:07Z","timestamp":1730895967000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-024-00657-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,6]]},"references-count":14,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["657"],"URL":"https:\/\/doi.org\/10.1007\/s40120-024-00657-y","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"type":"print","value":"2193-8253"},{"type":"electronic","value":"2193-6536"}],"subject":[],"published":{"date-parts":[[2024,9,6]]},"assertion":[{"value":"17 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Michael Lane has nothing to disclose. Michael Polydefkis has received consulting fees for Alnylam, AstraZeneca and Intellia, and was a principal investigator for the NEURO-TTRtrial.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}